Related Experiment Video

Updated: May 17, 2026

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
05:36

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

[Alteration of VHL gene in patients with metastatic renal cell carcinoma]

M V Peters, V B Matveev, M I Volkova

    Urologiia (Moscow, Russia : 1999)
    |October 19, 2012
    PubMed

    Insights

    VHL gene alterations, including mutations and methylation, were investigated in metastatic renal cell carcinoma patients receiving targeted therapy. These genetic changes did not significantly impact overall survival or treatment outcomes in this patient cohort.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Genetics

    Background:

    • Metastatic renal cell carcinoma (mRCC) is a complex malignancy.
    • Targeted therapies, particularly anti-angiogenic agents, are a cornerstone of mRCC treatment.
    • The VHL (von Hippel-Lindau) gene plays a critical role in regulating angiogenesis and is frequently altered in RCC.

    Purpose of the Study:

    • To investigate the frequency of VHL gene mutations and methylation in patients with mRCC undergoing targeted therapy.
    • To evaluate the impact of VHL gene alterations on clinical outcomes, including overall survival, progression-free survival, and relapse-free survival.

    Main Methods:

    • Analysis of tumor samples from 22 patients with mRCC.
    • Detection of VHL gene mutations and methylation using molecular techniques.
    • Correlation of VHL gene alteration status with patient survival data and treatment response.

    Main Results:

    • VHL gene mutations were identified in 45.5% (10/22) of patients.
    • VHL gene methylation was detected in 4.5% (1/22) of patients.
    • No statistically significant differences in overall survival, progression-free survival, or relapse-free survival were observed between patients with and without VHL gene alterations (p > 0.05).

    Conclusions:

    • VHL gene inactivation through mutation or methylation does not appear to influence the prognosis of metastatic renal cell carcinoma.
    • The presence of VHL gene alterations did not affect the efficacy of anti-angiogenic targeted therapy in this study cohort.

    More Related Videos

    Comparative Lesions Analysis Through a Targeted Sequencing Approach08:16

    Comparative Lesions Analysis Through a Targeted Sequencing Approach

    Published on: November 5, 2019

    Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells12:04

    Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

    Published on: March 10, 2023

    Related Concept Videos

    Rous Sarcoma Virus (RSV) and Cancer01:03

    Rous Sarcoma Virus (RSV) and Cancer

    Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
    RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
    The Retinoblastoma Gene01:20

    The Retinoblastoma Gene

    Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
    The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...